Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials

Abstract

IMPORTANCEAdverse events (AEs) after placebo treatment are common in randomized clinical drug trials. Systematic evidence regarding these nocebo responses in vaccine trials is important for COVID-19 vaccination worldwide especially because concern about AEs is reported to be a reason for vaccination hesitancy. OBJECTIVE To compare the frequencies of AEs reported in the placebo groups of COVID-19 vaccine trials with those reported in the vaccine groups. DATA SOURCES For this systematic review and meta-analysis, the Medline (PubMed) and Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched systematically using medical subheading terms and free-text keywords for trials of COVID-19 vaccines published up to July 14, 2021. STUDY SELECTION Randomized clinical trials of COVID-19 vaccines that investigated adults aged 16 years or older were selected if they assessed solicited AEs within 7 days of injection, included an inert placebo arm, and provided AE reports for both the vaccine and placebo groups separately. Full texts were reviewed for eligibility by 2 independent reviewers. DATA EXTRACTION AND SYNTHESIS Data extraction and quality assessment were performed independently by 2 reviewers, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline and using the Cochrane risk-of-bias tool. Meta-analyses were based on random-effects models. MAIN OUTCOMES AND MEASURESThe primary outcomes were the proportions of placebo recipients reporting overall, systemic, and local (injection-site) AEs as well as logarithmic odds ratios (ORs) to evaluate group differences. Outcomes were tested for significance using z tests with 95% CIs. RESULTSTwelve articles with AE reports for 45 380 participants (22 578 placebo recipients and 22 802 vaccine recipients) were analyzed. After the first dose, 35.2% (95% CI, 26.7%-43.7%) of placebo recipients experienced systemic AEs, with headache (19.3%; 95% CI, 13.6%-25.1%) and fatigue (16.7%; 95% CI, 9.8%-23.6%) being most common. After the second dose, 31.8% (95% CI, 28.7%-35.0%) of placebo recipients reported systemic AEs. The ratio between placebo and vaccine arms showed that nocebo responses accounted for 76.0% of systemic AEs after the first COVID-19 vaccine dose and for 51.8% after the second dose. Significantly more vaccine recipients reported AEs, but the group difference for systemic AEs was small after the first dose

Fever after Vaccination against SARS-CoV-2 with mRNA-Based Vaccine Associated with Higher Antibody Levels during 6 Months Follow-Up

“…These results support the findings of our study that previous COVID-19 infection compensates for the decrease in antibody levels following vaccination, an effect that occurs primarily in the late phase beyond 90 days. In a recent systematic review and meta-analysis, significantly more ARs were reported in vaccine groups compared with placebo groups after COVID-19 vaccination trials, but the rates of reported ARs in the placebo arms were still substantial [ 32 ]. The result of this work is remarkable, however, the study did not examine the rate of seroconversion or subsequent antibody response in the placebo group and the vaccine group.…”

Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine

“…One should note that this may not always be necessarily related to the vaccine constituents. Analysis of adverse events recorded in COVID-19 vaccine trials indicated that the rates of nocebo responses, i.e., unwanted effects seemingly elicited by placebo administration, are substantial [ 34 ]. This may be due to anxiety associated with intervention or misconceptions about potential side effects [ 35 ].…”

Vaccination against SARS-CoV-2 in UK school-aged children and young people decreases infection rates and reduces COVID-19 symptoms

“…It may be that only more severe systemic side effects were proxy-reported in our study. However, the nocebo effect may also be relevant in explaining the discrepancy (i.e., that individuals warned of potential side-effects may report them even when receiving the placebo), with a recent meta-analysis reporting extremely common nocebo responses in trials of COVID-19 vaccines (76.0% of systemic effects after first dose and 51.8% after second dose) 28 .…”